

Introducing Principal Investigator Dr. Cédric Tremblay

By CCMR

Tue Sep 27 16:52:00 CDT 2022



CancerCare Manitoba Research Institute (CCMR) is pleased to welcome Dr. Cédric Tremblay as Principal Investigator at CCMR. Dr. Tremblay joined CCMR on September 1, 2022, and he is Assistant Professor in the Department of Immunology at the University of Manitoba.

Dr. Tremblay is an emerging leader in translational research, and he has focused on understanding the molecular mechanisms underlying blood disorders and developing novel therapeutic strategies to improve the outcome for patients.

His current research program utilizes single-cell multi-omic approaches to investigate the molecular mechanisms that control

the fate of normal and malignant hematopoietic stem cells.

Dr. Tremblay completed his PhD in Molecular and Cellular Biology (Medicine) at Laval University, Canada and was awarded the prestigious Excellence Prize in Pediatric Research from the Foundation of Stars in 2008, recognizing his research contributions to improve outcomes for sick children.

He was awarded a Terry Fox Foundation fellowship from the Canadian Cancer Society for his postdoctoral work investigating the collaboration between oncogenes and signaling pathways in acute leukemia, in the laboratory of Dr. Trang Hoang at the Institute for Research in Immunology and Cancer (IRIC)/Université de Montréal. In 2011, he joined the Stem Cell Research group led by Dr. David Curtis at the Australian Centre for Blood Diseases (ACBD)/Monash University to investigate the molecular mechanisms involved in the development of malignant stem cells.

Dr. Tremblay was appointed as a research fellow in 2015, after receiving a Grant-in-Aid from the Leukaemia Foundation of Australia to establish a research program focused on the molecular mechanisms driving disease progression and relapse in T-cell Acute Lymphoblastic Leukemia (T-ALL).

Dr. Tremblay established his laboratory at CancerCare Manitoba Research Institute and his current research program has three key convergent axes: (1) defining the mechanisms by which malignant stem cells survive high-dose chemotherapy, (2) determining the role of the microenvironment in leukemia progression and relapse, and (3) developing innovative therapeutic strategies to improve outcomes for patients living with acute leukemia.

We are excited to have Dr. Tremblay on our team and we look forward to his contributions to pediatric research in acute leukemia. Welcome, Dr. Tremblay!

View more information about Dr. Tremblay:

ORCID (<https://orcid.org/0000-0003-2396-776X>)

(<https://orcid.org/0000-0003-2396-776X>)Research Gate

(<https://www.researchgate.net/profile/Cedric-Tremblay>)Google Scholar

(<https://scholar.google.com.au/citations?user=jrF427IAAAAJ&hl=en>)Twitter: @CedricSTremblay (<https://twitter.com/cedricstremblay?lang=en>) and @Tremblay_Lab

(https://twitter.com/Tremblay_Lab)LinkedIn (<https://www.linkedin.com/in/c%C3%A9dric-s-tremblay-phd-6084683b>)

(<https://www.researchgate.net/profile/Cedric-Tremblay>)